News
CMXHF
135.00
NaN%
--
Healthcare, Insurers 'Best Places to Hide' on AI Cycle Unwind Worries -- Market Talk
Dow Jones · 11/05 22:35
CSL Reports Further Share Buy-Back Activity
TipRanks · 11/05 22:21
*CSL Price Target Raised 12% to A$210.00/Share by Morgans
Dow Jones · 11/04 23:16
*CSL Downgraded to Hold from Buy by Morgans
Dow Jones · 11/04 23:16
CSL (CMXHF) was downgraded to a Hold Rating at Morgans
TipRanks · 11/04 22:36
CSL Reports 38,043 Shares Bought Back On-Market
TipRanks · 11/04 22:16
Morgan Stanley Reaffirms Their Buy Rating on CSL (CMXHF)
TipRanks · 11/04 00:55
UBS Remains a Buy on CSL (CMXHF)
TipRanks · 11/03 22:35
CSL Repurchases 56,067 Shares Under Buy-Back Program
TipRanks · 11/01 21:12
UBS Remains a Buy on CSL (CMXHF)
TipRanks · 10/30 04:35
*CSL Price Target Raised 24% to A$225.00/Share by UBS
Dow Jones · 10/30 02:00
CSL Reports Progress on Ongoing On-Market Share Buy-Back
TipRanks · 10/29 22:05
*CSL Price Target Raised 10% to A$178.00/Share by Jefferies
Dow Jones · 10/29 21:16
CSL Shareholders Back Board Changes and Pay at 2026 AGM
TipRanks · 10/27 03:07
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF), Ascendis Pharma (ASND) and Amgen (AMGN)
TipRanks · 10/26 00:20
CSL Names Gordon Naylor as Next Chair as Brian McNamee Sets Retirement Date
TipRanks · 10/25 22:32
Morgan Stanley Sticks to Its Buy Rating for CSL (CMXHF)
TipRanks · 10/23 00:35
Analysts Conflicted on These Healthcare Names: Newron Pharmaceuticals SpA (OtherNWPHF) and CSL (OtherCMXHF)
TipRanks · 10/22 13:10
Macquarie Reaffirms Their Hold Rating on CSL (CMXHF)
TipRanks · 10/22 01:15
CSL Limited hires GSK executive Waterhouse as new CEO
Seeking Alpha · 10/21 14:08
More
Webull provides a variety of real-time CMXHF stock news. You can receive the latest news about CSL through multiple platforms. This information may help you make smarter investment decisions.
About CMXHF
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.